Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gennex LaboratoriesBOM:531739 -2.47%79 Days Payable is 35.20 as of Mar. 2026, which is 53% below its 10-year median of 75.58. GuruFocus rates BOM:531739 with a GF Score™ of 79/100 and a GF Value™ of ₹15.52 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 925 Drug Manufacturers companies, Gennex Laboratories ranks worse than 77.41% on this metric.
The historical rank and industry rank for Gennex Laboratories's Days Payable or its related term are showing as below:
BOM:531739'
s Days Payable Range Over the Past 10 Years
Min: 47.33 Med: 75.58 Max: 140.33
Current: 47.33
During the past 13 years, Gennex Laboratories's highest Days Payable was 140.33. The lowest was 47.33. And the median was 75.58.
BOM:531739's Days Payable is ranked worse than 77.41% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs BOM:531739: 47.33
Gennex Laboratories's Days Payable
declined
from Mar. 2025 (37.18) to Mar. 2026 (35.20).
It may suggest that Gennex Laboratoriesaccelerated paying its suppliers.
Gennex Laboratories Days Payable Related Terms
Gennex Laboratories Days Payable Historical Data
* Premium members only.
The historical data trend for Gennex Laboratories's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gennex Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gennex Laboratories Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gennex Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Gennex Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Gennex Laboratories's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gennex Laboratories (BOM:531739) has a Days Payable of 35.20 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gennex Laboratories and its competitors. This is 53% below median its historical median of 75.58. Over the past decade, Gennex Laboratories' Days Payable has ranged from 47.33 to 140.33. According to the industry distribution chart, Gennex Laboratories ranks #716 out of 925 companies in the Drug Manufacturers industry, placing it in the top 77.4%.
Is Gennex Laboratories' Days Payable too high?
Gennex Laboratories' current Days Payable of 35.20 is 53% below median its 10-year median of 75.58. Over the past 10 years, this metric has ranged from a low of 47.33 to a high of 140.33. The Drug Manufacturers industry median Days Payable is 90.38. Gennex Laboratories' value of 35.20 is 61.1% below this industry median. Based on the distribution chart, Gennex Laboratories ranks #716 out of 925 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Gennex Laboratories has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gennex Laboratories' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gennex Laboratories ranks #716 out of 925 companies for Days Payable. This places Gennex Laboratories in the lower half of its industry. The industry median Days Payable is 90.38. Gennex Laboratories' value of 35.20 is 61.1% below this benchmark. Historically, Gennex Laboratories' own Days Payable has ranged from 47.33 to 140.33 over the past decade. While the company's 10-year median is 75.58 vs. the industry median of 90.38, Gennex Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gennex Laboratories's current Days Payable of 35.20 is 61.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gennex Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gennex Laboratories's current Days Payable is 35.20, which is 53% below median its own 10-year median of 75.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gennex Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Gennex Laboratories (BOM:531739) is currently considered Possible Value Trap. The stock's GF Value™ is ₹15.52, compared to a current price of ₹9.10 — trading 41.4% below its estimated fair value. The current Days Payable is 35.20, which is 53% below median its 10-year median of 75.58 and 61.1% below the Drug Manufacturers industry median of 90.38. Gennex Laboratories' overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Gennex Laboratories (BOM:531739), the current Days Payable is 35.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gennex Laboratories (BOM:531739) Overvalued in 2026?
Based on GuruFocus' analysis, Gennex Laboratories stock appears to be undervalued.
The current stock price of ₹9.10 is trading 41.4% below its estimated GF Value™ of ₹15.52.
GuruFocus considers Gennex Laboratories to be Possible Value Trap.
Key valuation signals for BOM:531739:
Days Payable: 35.20 (53% below median its 10-year median of 75.58)
GF Value™: ₹15.52 vs. price of ₹9.10 (41.4% below fair value)
Industry Position: 61.1% below the Drug Manufacturers median (#716 of 925)
No single metric tells the full story. See the BOM:531739 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gennex Laboratories Ltd is engaged in the manufacturing of bulk drugs, and intermediates, Biotech Products. Geographically, the group has a business presence in Bangladesh, Egypt, Germany, Guatemala, Iran, Israel and other countries. Its products include Guaifenesin, Methocarbamol, Fluconazole and Phenazopyridine, among others.
79GF Score
Get the complete analysis for BOM:531739
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531739 has been successfully added to your 
